Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Tisch Hospital · Tisch Cancer Institute · +29 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
782
total citations
- FWCI
- 114.45
- Percentile
- 100%
- References
- 26
Citations per year
Authors
26- MDMatthew D. GalskyCorresponding
Tisch Hospital, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
- JÁJóse Ángel Arranz Arija
Hospital General Universitario Gregorio Marañón
- ABAristotelis Bamias
National and Kapodistrian University of Athens
- IDIan D. Davis
Eastern Health, Monash University
- MDMaria De Santis
Medical University of Vienna, Charité - Universitätsmedizin Berlin
Topics & keywords
Topics
Keywords
- Atezolizumab
- Medicine
- Metastatic Urothelial Carcinoma
- Placebo
- Carboplatin
- Gemcitabine
- Chemotherapy
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.